MARKET

OKYO

OKYO

OKYO PHARMA LTD
NASDAQ
1.750
-0.420
-19.35%
After Hours: 1.800 +0.05 +2.86% 19:43 02/13 EST
OPEN
1.850
PREV CLOSE
2.170
HIGH
1.850
LOW
1.550
VOLUME
2.10M
TURNOVER
--
52 WEEK HIGH
3.349
52 WEEK LOW
1.010
MARKET CAP
70.97M
P/E (TTM)
-11.4454
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 1d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 1d ago
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
TipRanks · 1d ago
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
TipRanks · 1d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 1d ago
OKYO Pharma prices public offering at $1.85/share to raise up to $20M
Seeking Alpha · 1d ago
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
TipRanks · 2d ago
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
TipRanks · 2d ago
More
About OKYO
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Webull offers OKYO Pharma Ltd stock information, including NASDAQ: OKYO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OKYO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OKYO stock methods without spending real money on the virtual paper trading platform.